Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $195.28 and traded as high as $202.90. Genmab A/S shares last traded at $199.35, with a volume of 139 shares traded.
Genmab A/S Stock Performance
The stock has a market capitalization of $13.77 billion, a P/E ratio of 11.89 and a beta of 1.02. The business has a fifty day simple moving average of $195.45 and a 200-day simple moving average of $205.81.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $3.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. The firm had revenue of $765.14 million for the quarter, compared to analysts' expectations of $761.09 million. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
